Silver linings: a qualitative study of desirable changes to cancer care during the COVID-19 pandemic

Glow study: MRD outcomes after fixed-duration Ibr+Ven versus Clb+O for first-line treatment of CLL in elderly or unfit patients

Tisagenlecleucel shows no EFS improvement on standard of care in 2L for aggressive B-cell NHL

Integrated genomic analysis identifies UBTF tandem duplications as a subtype-defining lesion in paediatric AML

Asciminib found to be safe and effective for heavily pretreated patients with chronic myeloid leukaemia in chronic phase

Long-term OS benefit with oral azacitidine for acute myeloid leukaemia in first remission after intensive chemo

Allogeneic haematopoietic cell transplantation in adults with Ph-like ALL

Azacitidine, venetoclax and gilteritinib for FLT3-mutated AML

Ten-day decitabine with venetoclax in acute myeloid leukaemia: Updated outcomes across genomic subgroups

Axicabtagene ciloleucel vs standard‑of‑care therapy for relapsed/refractory large B-cell lymphoma

EURO-SKI: 46% of CML patients still in molecular recurrence- and treatment-free survival 3 years after TKIs

Clinical utility of molecular tumour profiling in breast cancer